Benefits
Raised brain EPA, but not DHA, in mice
In the animal study cited here, mice carrying the human APOE3 or APOE4 gene were given omega-3 attached to lysophosphatidylcholine. EPA rose in the brain cortex. DHA did not. That is a partly negative result, because DHA is the omega-3 most linked to brain and retina function. None of this has been measured in people, and fatty acid levels in brain tissue are a laboratory reading, not a memory or vision result.
Brain delivery route: mechanism only, never tested in people
MFSD2A (Major Facilitator Superfamily Domain Containing 2A) is the major transporter for DHA/EPA uptake into the brain — and only recognizes esterified DHA/EPA in LPC form. Ordinary fish or krill oil, where the omega-3 is carried as a triglyceride or phospholipid, is thought to use this transporter less well. All of that comes from structural biology and animal work. No study has shown that taking this ingredient raises omega-3 levels in a human brain, or changes anything a person would notice.
Membrane phospholipid building blocks
LPC delivery provides not just the omega-3 fatty acids but also the LPC carrier itself as substrate for neuronal membrane phospholipid synthesis. Brain cells turn over phospholipids quickly, so in theory supplying both parts could help. This is an untested idea. Nothing cited on this page compared this ingredient against an ordinary omega-3 supplement in people.
FDA safety notification accepted (not an approval)
FDA accepted the manufacturer's new dietary ingredient (NDI) notification for use at up to 1.5 g/day in adults. An NDI notification means the company submitted safety information and FDA did not object. It is not FDA approval, and it says nothing about whether the ingredient improves memory or vision. Lysoveta is the first commercially available LPC-bound omega-3 ingredient on the market.
Patented manufacturing process (not evidence of benefit)
The manufacturer reports 40 patents in 16 countries covering how the ingredient is made. Patents show that a production method is considered novel. They are not evidence that a supplement does anything for your health, and no patent office reviews health effects.
Eye health: a theory only, with no eye studies behind it
The same MFSD2A transporter is also found at the barrier between the blood and the retina, where it moves omega-3 into the eye. In theory the LPC form would use that route as well. That is where the evidence stops: not one reference on this page measured eyesight, macular health or any other eye outcome, in people or in animals. If you have an eye condition, see an eye doctor.
Mechanism of action
MFSD2A transporter recognition
MFSD2A is a major facilitator superfamily transporter expressed on brain endothelial cells (BBB) and retinal pigment epithelium. It specifically recognizes LPC esters of omega-3 PUFAs and transports them into brain/eye tissue, the essential brain omega-3 uptake mechanism. This ingredient supplies EPA and DHA in the LPC form that this transporter carries. That comes from structural biology of the transporter protein, not from any study of people taking the supplement.
Bypassing TG/PL hydrolysis
Standard fish oil (TG) and krill oil (PL) omega-3s undergo intestinal and circulating hydrolysis to free fatty acids before reaching brain endothelium. Free fatty acids cross BBB inefficiently — MFSD2A doesn't recognize them. The idea is that pre-formed LPC omega-3 skips this step. It has not been confirmed in people.
Neuronal membrane DHA enrichment
Brain DHA is concentrated in neuronal membrane phospholipids — especially in synaptic regions. Adequate brain DHA supports membrane fluidity, synaptic function, and resolution of neuroinflammation. Worth noting: in the mouse study cited on this page, brain DHA did not rise with LPC-bound omega-3. Only EPA rose.
EPA-specific anti-neuroinflammatory effects
EPA produces specialized pro-resolving mediators (SPMs) including E-series resolvins. Since the mouse study showed EPA rising in the brain while DHA did not, any brain effect of this form would have to come mostly from EPA. That is a hypothesis. No study cited here measured inflammation, mood or thinking in people.
Clinical trials
Announced by the manufacturer. No results have been published, so there is nothing here to evaluate yet.
138 healthy adults aged 50-75 with mild memory complaints
There are no results from this study. The manufacturer, Aker BioMarine, hired a contract research company (KGK Science) to run what would be the first human trial of the ingredient: 138 adults aged 50 to 75 with mild memory complaints, looking at memory and thinking. Nothing has been published, so it tells you nothing about whether the ingredient works. It is also manufacturer funded, which is worth keeping in mind whenever results do appear.
A protein structure study plus mouse research. This is not a clinical trial and involved no people.
No people at all. The cited work is a protein structure study, plus mouse research.
This is not a clinical trial. The paper cited (Nature Communications 2023) is a structural biology study of the MFSD2A transporter protein itself, imaged with cryo-electron microscopy. It has no participants, no supplement and no health outcome. The only animal study on this page (mice with the human APOE3 or APOE4 gene) found that LPC-bound omega-3 raised EPA in the brain cortex but did not raise DHA. The 40 mg/kg dose and the 2-fold DHA figure quoted here do not come from any study in the reference list.